Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5844271

CCC1CCN(c2ccncc2)CC1.N

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHKA P35790 1/20 0.52
ADRB2 P07550 1/20 0.47
NCF1 P14598 1/20 0.47
PLD1 Q13393 1/20 0.47
CDK1 P06493 1/20 0.43
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
DHFR P00374 1/20 0.42
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP19A1 P11511 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
F10 P00742 1/20 0.40
KHK P50053 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5803729 0.98 CHKA (0.53) CHKAADRB2NCF1PLD1CDK1
SCHEMBL21101188 0.84 CHKA (0.50) CHKAADRB2NCF1PLD1DPP4
SCHEMBL28179029 0.83 CYP2C19 (0.49) CHKAADRB2NCF1PLD1HRH3
SCHEMBL13083096 0.80 F10 (0.47) CHKAADRB2NCF1PLD1KDM1A
SCHEMBL785122 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1DPP4
SCHEMBL4717561 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1DPP4
SCHEMBL4713972 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1DPP4
SCHEMBL5760023 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1DPP4
SCHEMBL1648623 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1KDM1A
SCHEMBL26627856 0.80 CHKA (0.53) CHKAADRB2NCF1PLD1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074783-B2 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-07-11 US disclosed
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138208-A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists BDKRB1, BDKRB2, HRH2 CHKA 808/4885ADRB2 268/4885NCF1 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.